PD-1抑制剂联合化疗对比贝伐珠单抗联合化疗一线治疗非鳞非小细胞肺癌的研究  

PD-1 inhibitor combined with chemotherapy versus bevacizumab combined with chemotherapy as first-line treatments for advanced non-squamous non-small cell lung cancer:a retrospective study

作　　者：郑飞[1] 李曙光[2] 黄芳[1] 史健[1] 刘义冰[1] Fei Zheng;Shuguang Li;Fang Huang;Jian Shi;Yibing Liu(Department of Oncology,The Fourth Hospital of Hebei Medical University,Shijiazhuang 050011,China;Department of Radiotherapy,The Fourth Hospital of Hebei Medical University,Shijiazhuang 050011,China)

机构地区：[1]河北医科大学第四医院肿瘤内科,石家庄市050011 [2]河北医科大学第四医院放疗科,石家庄市050011

出　　处：《中国肿瘤临床》2024年第15期769-774,共6页Chinese Journal of Clinical Oncology

基　　金：河北省2024年度医学科学研究计划项目(编号:20241327)。

摘　　要：目的比较细胞程序性死亡受体-1(programmed cell death protein-1,PD-1)抑制剂联合化疗与贝伐珠单抗联合化疗一线治疗晚期非鳞非小细胞肺癌(non-squamous non-small cell lung cancer,nsNSCLC)的疗效。方法回顾性收集2014年11月至2024年3月于河北医科大学第四医院接受一线治疗的晚期nsNSCLC患者237例。根据治疗方案分为PD-1抑制剂联合化疗(IC组)119例和贝伐珠单抗联合化疗(BC组)118例。采用倾向得分匹配(propensity score matching,PSM)平衡协变量。研究主要终点为无进展生存期(progression-free survival,PFS),次要终点为客观缓解率(objective response rate,ORR)、疾病控制率(disease control rate,DCR)、总生存期(overall survival,OS)。结果237例患者经PSM后IC组和BC组各87例,IC组和BC组的ORR分别为31.0%(27/87)和43.7%(38/87)(P=0.085),DCR为96.6%(84/87)和95.4%(83/87)(P=1.000)。中位PFS IC组为9.3个月,BC组为9.1个月,两组差异无统计学意义(P=0.053)。OS两组差异无统计学意义(两组均未达到中位OS,P=0.116)。结论PD-1抑制剂联合化疗对比贝伐珠单抗联合化疗一线治疗晚期nsNSCLC近期疗效无差异。Objective To compare the efficacy of programmed death-1(PD-1)inhibitors combined with chemotherapy with that of bevacizumab combined with chemotherapy as first-line treatments for advanced non-squamous non-small cell lung cancer(nsNSCLC).Methods Retrospective collection of 237 patients with advanced nsNSCLC who received first-line treatment at the Fourth Hospital of Hebei Medical University from November 2014 to March 2024.According to the treatment plan,119 cases were assigned into PD-1 inhibitor combined with chemotherapy(IC group)and 118 cases were assigned into bevacizumab combined with chemotherapy(BC group).Propensity score matching(PSM)was used to balance covariates.The primary endpoint was progression-free survival(PFS),and the secondary endpoints were objective response rate(ORR),disease control rate(DCR),and overall survival(OS).Results Among 237 patients with PSM,87 were assigned to the IC group and 87 to the BC group,with respective ORRs of 31.0%(27/87)and 43.7%(38/87)(P=0.085)and respective DCRs of 96.6%(84/87)and 95.4%(83/87)(P=1.000).No significant difference in the median PFS was observed between the two groups,with a PFS value of 9.3 months in the IC group and 9.1 months in the BC group(P=0.053).In addition,the two groups also showed no significant difference in OS(neither group reached the median OS;P=0.116).Conclusions There was no significant difference in the short-term efficacy between chemotherapy combined with PD-1 inhibitor and that combined with bevacizumab as first-line treatments for advanced nsNSCLC.

关 键 词：PD-1抑制剂 贝伐珠单抗 非鳞非小细胞肺癌 

分 类 号：R734.2[医药卫生—肿瘤]